Eli Lilly & Co. 10-K Summary (Fiscal Year Ended Dec 31, 1999)
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 1999, for Eli Lilly and Company, an Indiana corporation founded in 1876. The Company operates in one significant business segment: pharmaceutical products. Its animal health business segment is not material to financial statements. Operations include manufacturing and distribution in the U.S., Puerto Rico, and 28 other countries, with products sold in approximately 160 countries. In January 1999, the Company completed the sale of its PCS Health Systems business.
Key Financial Metrics
The filing text incorporates detailed financial statements by reference to the 1999 Annual Report and does not explicitly state consolidated revenue, net income, or cash flow figures within the provided text. However, the following specific data points are disclosed:
- Research and Development (R&D): $1.78 billion in 1999 (up from $1.74 billion in 1998 and $1.37 billion in 1997).
- Employees: Approximately 31,300 total at year-end, including 6,050 in R&D and 15,800 outside the U.S.
- Market Capitalization: Aggregate market value of voting stock held by non-affiliates was $56,399,202,838 as of February 15, 2000.
- Outstanding Shares: 1,092,565,591 shares of common stock as of February 15, 2000.
- Debt Instruments: Multiple notes registered, including 8 1/8% Notes (2001), 8 3/8% Notes (2006), 6.57% Notes (2016), 7 1/8% Notes (2025), and 6.77% Notes (2036).
Material Changes and Operational Highlights
The most significant operational change was the divestiture of the PCS Health Systems business in January 1999. The Company continues to invest heavily in R&D, with expenditures increasing for the third consecutive year. Neuroscience products remain the largest-selling product group, led by Prozac and Zyprexa. The Company noted that three U.S. wholesale distributors accounted for approximately 46% of consolidated net sales in 1999 (18%, 15%, and 13% respectively).
Outlook, Risks, and Contingencies
Patent Expirations and Litigation: The Company faces significant litigation regarding the patents for Prozac. The U.S. compound patent expires in February 2001, and a method-of-use patent expires in December 2003. Generic manufacturers (Barr, Geneva, Zenith, Teva, Cheminor, Novex) have challenged these patents. While the Company won partial summary judgment in early 1999 and settled some claims for $4 million, appeals are pending. An unfavorable outcome could materially adversely affect financial position.
Product Liability and Pricing: The Company is a defendant in product liability suits involving DES and Prozac. Additionally, it faces extensive pricing litigation regarding antitrust and price discrimination claims from retail pharmacies and consumers. Settlements have been reached with many plaintiffs, but some individual actions remain pending.
Regulatory Environment: Operations are subject to extensive government regulation regarding testing, approval, and pricing. Cost containment measures, including price controls and rebates, are prevalent in both U.S. and international markets.
Investor Verification Checklist
- Verify the outcome of the Prozac patent litigation appeals, specifically regarding the February 2001 compound patent expiration.
- Review the 1999 Annual Report (Exhibit 13) for specific consolidated revenue, net income, and cash flow figures not detailed in this 10-K text.
- Assess the financial impact of the pending pricing litigation settlements and the remaining individual actions.
- Monitor the pipeline for new products to offset the anticipated loss of exclusivity for Prozac and other key drugs (e.g., Axid in 2002).
- Confirm the status of the $4 million settlement payment to generic manufacturers and any subsequent legal costs.